Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.

Matthew K Smith,Yin Chan,Aleksi E Suo,Abdel Aziz Shaheen,Stephen E Congly,Puneeta Tandon,Rahima A Bhanji, Malcolm M Wells,Tina Cheng,Christopher Ma

Journal of the Canadian Association of Gastroenterology（2022）

引用 2|浏览7

暂无评分

摘要

Approximately half of the patients treated with combination ipilimumab and nivolumab developed IMH in this cohort. However, most patients experienced uncomplicated IMH resolution.

查看译文

关键词

Hepatitis,Immune checkpoint inhibitor,Immune-related adverse event,Ipilimumab,Nivolumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要